Background
==========

We have recently described homo-and heterodimerization of somatostatin receptor (SSTR) subtypes and its functional consequences on receptor trafficking and signaling in response to agonist activation. SSTRs heterodimerization is not restricted to its own family but has also been demonstrated with other member of G-protein coupled receptors (GPCRs) family such as dopamine and opioid receptors as well as with the members of receptor tyrosine kinase family \[[@B1]-[@B4]\]. In several pathological conditions including neurodegenerative diseases and tumors of different origin, somatostatin (SST) via its five receptor subtypes plays crucial role and serves as an important therapeutic approach. Most recent example of clinical implication of heterodimerization is the development of chimeric molecules of hSSTR5 and dopamine receptor 2 in treatment of pituitary tumor \[[@B5],[@B6]\].

Adrenergic receptors (ARs) specifically β~1~AR and β~2~AR are the prominent receptor subtypes from GPCR family and have provided first convincing evidence in support of GPCRs dimerization \[[@B7]-[@B13]\]. β~1~AR and β~2~AR exhibit some similarities, but also exert receptor specific role on signaling molecules including receptor dependent stimulation of apoptosis and mitogen activated protein kinases (MAPKs). Widespread distributions of AR subtypes in different tissues provide the broad spectrum of physiological importance specifically in cardiac physiology \[[@B10],[@B14]-[@B17]\]. However, the direct mechanistic and physiological importance of the ARs in heart failure is derived from the β~1~and β~2~AR knockout and the transgenic mice \[[@B16]-[@B19]\].

SSTR subtypes are also well expressed in cardiac tissues and have been attributed to the beneficial role in cardiac physiology and are associated with positive and negative contractile function in concentration dependent manner \[[@B20]-[@B22]\]. Most importantly in patients with pituitary tumor (acromegaly) and Huntington\'s disease (HD), the high mortality rate is associated with cardiovascular diseases \[[@B23]\]. These significant observations anticipate the possibility of functional interaction between SSTR and β-AR subtypes. SSTRs and β-ARs have been studied extensively for homo-and heterodimerization within the family and with dopamine and opioid receptors with physiological significance and clinical implications \[[@B2],[@B4],[@B8],[@B13],[@B24]-[@B30]\]. There is no direct evidence whether SSTR and β-AR subtypes functionally interact with each other. Although, as early as in 1985, a study has described that in rat brain astrocytes, SST enhanced the production of β-AR mediated cyclic adenosine monophosphate (cAMP) \[[@B31]\]. In addition, agonist occupied β-AR gets phosphorylated in presence of β-AR kinase and SST and isoproterenol displayed similar effect in promoting the translocation of β-AR kinase \[[@B32],[@B33]\]. Recently, we have shown the distributional pattern and colocalization of SSTRs and β-ARs in H9c2 cells \[[@B34]\]. In addition, we have described the functional interaction between SSTR5 and β~1~AR in human embryonic kidney cells (HEK-293 cells) \[[@B35]\]. These studies further support our concept and are compelling evidences to predict the functional interaction between adrenergic and somatostatin receptors in a receptor specific manner.

Accordingly, in the present study by using morphological, biochemical and biophysical techniques, we studied the heterodimerization between G~i~-coupled hSSTR5 and G~s~-coupled β~2~AR in HEK-293 stably cotransfected with both receptors and compared with monotransfected cells. We also analyzed receptor trafficking, coupling to adenylyl cyclase and downstream signaling cascades including extracellular signal-regulated kinases (ERK1/2), p38, protein kinase A (PKA) and nuclear transcriptional factor (NFAT) in mono-and/or cotransfected cells. Our results showed that hSSTR5/β~2~AR exhibits heterodimerization in basal condition or upon combined activation and modulate signaling pathways in receptor specific manner.

Materials and methods
=====================

Materials
---------

Somatostatin-14 was obtained from Bachem, Torrance, CA. β~2~AR agonist formoterol hemifumarate and antagonist ICI-118551 was purchased from Tocris Cookson Inc., Ellisville, Missouri, USA. The non-peptide agonist L-817818 (hSSTR5) was provided by Dr. S.P. Rohrer from Merck & Co \[[@B36]\]. Monoclonal and polyclonal antibodies against HA- and cMyc- and β-actin were procured from Sigma-Aldrich, Inc., St. Louis, MO. Fluorescein and rhodamine conjugated goat-anti-mouse and goat-anti-rabbit secondary antibodies were purchased from Jackson Immuno Research ON. Polyclonal antibodies for total and phospho-ERK1/2 (phosphorylation site-Thr202/Tyr204) and p38 (phosphorylation site- Thr180/Tyr182) were obtained from Cell Signaling Technology, Danvers, MA. Antibodies for total and phospho-PKA (phosphorylation site-Thr198) and NFAT (phosphorylation site-Ser265) were purchased from Santa Cruz Biotechnology, Santa Cruz, CA. cAMP assay kit was purchased from BioVision, Inc. CA, USA. Protein A/G-Agarose beads were procured from Calbiochem, EMD Biosciences, Darmstadt, Germany. Reagents for electrophoresis were purchased from BIO-RAD Laboratories Mississauga ON, Canada. 4\',6-diamidino-2-phenylindole (DAPI) dihydrochloride was purchased from Molecular Probes, Inc., Eugene, OR. Reagents for cell culture were purchased from GIBCO, Invitrogen, Burlington, ON, Canada. Other reagents were of AR grade and were procured from various sources.

Receptor Constructs and Cell Lines
----------------------------------

cMyc-β~2~AR in pCDNA3.1^+^/Hygro vector (hygromycin resistance) was purchased from TOP Gene Technologies, Montreal, Canada. Construct of HA-SSTR5 was made using the pCDNA3.1^+^/Neo (neomycin resistance) as previously described \[[@B2],[@B24],[@B25],[@B37]\]. The stable transfections of HA-hSSTR5 and cMyc- β~2~AR in HEK-293 cells were prepared by Lipofectamine transfection reagent as described \[[@B1],[@B2],[@B24],[@B25],[@B37]\]. Cotransfection of cMyc-β~2~AR in the HEK-293 cells stably expressing HA-hSSTR5 was performed using Lipofectamine transfection reagent and the cells were maintained in Dulbecco\'s MEM supplemented with 10% fetal bovine serum (FBS), 700 μg/ml neomycin and 400 μg/ml hygromycin as described earlier \[[@B1],[@B2],[@B24],[@B25],[@B37]\].

Co-immunoprecipitation (Co-IP)
------------------------------

HEK-293 cells cotransfected with cMyc-β~2~AR/HA-hSSTR5 were treated with SST (1 μM) and formoterol (1 μM) alone or in combination for 30 min at 37°C. Membrane protein (250 μg) was solubilized in 1 ml of radioimmune precipitation assay buffer (RIPA Buffer, 150 mM NaCl, 50 mM Tris-HCL, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, pH 8.0) for 1 h at 4°C and Co-IP was performed as previously described \[[@B35]\]. Briefly, samples were incubated with 1 μg antibody overnight at 4°C. 25 μl of protein A/G-agarose beads were added to immunoprecipitate antibody for 2 h at 4°C. Beads were washed and solubilized in Laemmli sample buffer (Bio-Rad) and fractionated by electrophoresis on a 10% SDS-polyacrylamide gel. The fractionated proteins were transferred to a 0.2 μm nitrocellulose membrane and blotted with anti-HA or anti-cMyc antibody (dilution 1:500) for the expression of HA-hSSTR5 and cMyc-β~2~AR and detected by chemiluminescence using ECL Western blotting detection kit (Amersham) according to the manufacturer\'s instructions \[[@B24],[@B37]\]. Images were captured using an Alpha Innotech FluorChem 8800 gel box imager (Alpha Innotech Co., San Leandro, CA).

Photobleaching- Fluorescence Resonance Energy Transfer (Pb-FRET) Microscopic Analysis
-------------------------------------------------------------------------------------

HEK-293 cells expressing cMyc- β~2~AR/HA-hSSTR5 were grown on poly-D-lysine coated glass coverslips to 60-70% cell confluency. Cells were treated with 1 μM SST and 1 μM β~2~agonist alone or in combination for 15 min at 37°C and fixed with 4% paraformaldehyde for 20 min on ice and were further processed for immunofluorescence immunocytochemistry \[[@B24],[@B35],[@B37]\]. Monoclonal anti-HA and polyclonal anti-cMyc primary antibodies were used followed by FITC- and Cy3- conjugated secondary antibodies to create donor-acceptor pair. The plasma membrane region was used to analyze the photobleaching decay on a pixel-by-pixel basis as previously described \[[@B24],[@B37]\]. The FRET efficiency (E) was calculated in terms of a percent based upon the photo bleaching (Pb) time constants of the donor taken in the absence (D-A) and presence (D+A) of acceptor and relative FRET efficiency was calculated as previously described \[[@B35]\].

Receptor Internalization
------------------------

To study receptor internalization, HEK-293 cells stably expressing cMyc-β~2~AR/HA-hSSTR5 were grown on poly-D-Lysine coated coverslips to 60-70% cell confluency. Cells were treated with SST (1 μM) and formoterol (1 μM) alone or in combination for 15 min at 37°C and were processed for immunocytochemistry as previously described \[[@B25],[@B35],[@B37]\]. Receptor expression in both non-permeabilized and permeabilized cells was analyzed by using Leica DMLB microscope attached with the Retiga 2000R camera. DAPI dihydrochloride was used for nuclear staining. Adobe Photoshop was used to construct figure composites and merged images displaying colocalization were generated by using Image J software, NIH.

Fluorescence assisted cell sorting (FACS) Analysis
--------------------------------------------------

The changes in cell surface expression of receptors and measurement of FRET was also performed by using a FACS. Approximately 2 × 10^6^cells were treated with SST, formoterol and CGP alone or in combination for 15 min at 37 C in DMEM. Cells were washed with FACS buffer (PBS pH7.4, 5% FBS, 2 mM EDTA), fixed in 4% paraformaldehyde and were processed for immunostaining. Anti-HA and anti-cMyc primary antibodies were used followed by FITC- and Cy3- fluorescence conjugated secondary antibodies. Non-stained cells were used to setup the background level of fluorescence whereas; control cells stained with either Cy3- or FITC- was used as fluorescence control. A BD LSRII flow cytometer, configured with a 488 nm and 561 nm laser was used for the experiments. The level of Cy3- was monitored using the 561 nm laser and a 610/20 emission filter to directly measure the β~2~AR expression levels. The cells were excited with the 488 nm laser first and the emission was detected using a 530/30 filter to detect the SSTR5 expression level whereas a 610/20 filter was used to detect any Cy3 emission due to FRET between SSTR5 and β~2~AR. Data analysis was done by using FlowJo 7.6 software.

Receptor Coupling to Adenylyl Cyclase (AC)
------------------------------------------

Briefly, to determine the basal levels of cAMP, transfected cells were incubated for 30 min with receptor specific agonists alone or in combination at 37°C in presence of 0.5 mM 3-isobutyl-1-methylxanthine. Similarly, cells were also incubated for 30 min with receptor specific agonist alone or in combination at 37°C in presence of 20 μM forskolin (FSK) and 0.5 mM 3-isobutyl-1-methylxanthine. Control and treated cells were then scraped in 0.1 N HCl and cAMP was determined by immunoassay using a cAMP Kit from BioVision, Inc. CA, USA according to the manufacturer\'s guidelines \[[@B24],[@B37]\].

To determine the G-proteins coupling with β~2~AR and SSTR5 in mono- and/or cotransfected cells, G-Protein antagonizing peptide (GPAP) or Melittin and Pertussis toxin (PTX) were used to inhibit G~s~and G~i~respectively. Mono-and cotransfected HEK-293 cells expressing cMyc-β~2~AR and/or HA-hSSTR5 were grown in 6 well culture plates and used at \> 70% cell confluency for cAMP assay \[[@B37]\]. In addition to the receptor specific agonist/antagonists, cells were also treated with GPAP (5 μM) and Melittin (1 μM) for 2 h and PTX (100 ng/ml) for 16-18 h in DMEM at 37°C and processed for cAMP estimation.

Western blot analysis
---------------------

HEK-293 cells monotransfected with β~2~AR or hSSTR5 were treated with receptor specific agonist whereas cells coexpressing β~2~AR/hSSTR5 were treated with SST (1 μM), L-817818 (10 nM) and formoterol (1 μM) alone or in combination for 10 min and 30 min at 37°C. Whole cell lysate prepared from cells were fractionated via SDS-PAGE and transferred to a 0.2 μM nitrocellulose membrane. Immunoblotting for ERK1/2 and p38 were performed by using respective phospho-and total specific antibodies and the bands were quantified by densitometry using FluorChem software as described earlier \[[@B35]\]. β-actin was used as loading control.

To determine the expression of total- and phospho-PKA and NFAT, mono- and/or cotransfected HEK-293 cells were treated with 1 μM SST, 10 nM L-817818, 1 μM formoterol alone or in combination for 10 or 30 min at 37°C in the medium containing 1.8 mM or 2.5 mM Ca^2+^. Cells were further processed and western blot was performed accordingly as described earlier \[[@B24],[@B37]\].

Statistical Analysis
--------------------

Results are presented as mean ± S.E unless otherwise stated. Statistical analysis was carried out using Graph Pad Prism 4.0 and statistical differences were taken at *p*values \< 0.05. The results presented here represent three independent experiments.

Results
=======

Human somatostatin receptor 5 and β~2~adrenergic receptor are constitutive heterodimers
---------------------------------------------------------------------------------------

To ascertain whether β~2~AR and hSSTR5 exists as heterodimers, we first determined heterodimerization using Co-IP in stably cotransfected HEK-293 cells. Membrane preparation from control and treated cells were immunoprecipitated for cMyc-β~2~AR and probed with antibody directed against HA to recognize HA-hSSTR5. As shown in Figure [1A](#F1){ref-type="fig"}, upon treatment with SST and formoterol alone or in combination, a band at \~110 kDa, the expected size of HA-hSSTR5/cMyc-β~2~AR heteromeric complex was detected in cMyc immunoprecipitate. To further confirm the specificity of the blot, same membrane was striped and reprobed with the anti-cMyc antibody to determine the expression of cMyc-β~2~AR. As shown in Figure [1B](#F1){ref-type="fig"}, monomers and homodimers of β~2~AR as well as heterodimers of hSSTR5/β~2~AR were observed at the expected molecular size of \~60 kDa, \~130 kDa and \~110 kDa respectively. The immunoprecipitate prepared from hSSTR5 or β~2~AR monotransfected cells probed reciprocally were devoid of any heteromeric complex (Figure [1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}).

![**Heterodimerization of hSSTR5 and β~2~AR in cotransfected HEK-293 cells**. Mono-and/or cotransfected cells were treated as indicated for 30 min at 37°C. A single band at the expected size of \~110 kDa an indicative of β~2~AR/hSSTR5 heterodimers was observed in β~2~AR immunoprecipitate **(arrow panel A)**. Same membrane was reprobed for β~2~AR expression using anti-cMyc specific antibody for the specificity of heterodimers **(arrow panel B)**. A band at the expected size of \~50 kDa was also seen for β~2~AR monomers. For specificity, monotransfected cells expressing SSTR5 or β~2~AR were used. No bands at the expected molecular weights were observed in either control or treated condition indicating the specificity of heterodimerization **(Panels C and D)**. Data are representative of three independent experiments.](1750-2187-6-9-1){#F1}

Microscopic Photobleaching Fluorescence resonance energy transfer (Pb-FRET)
---------------------------------------------------------------------------

Heterodimerization between hSSTR5/β~2~AR as seen in Co-IP assay was further confirmed by microscopic Pb-FRET analysis (Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). Cells were processed for receptor expression by using monoclonal anti-HA and polyclonal anti-cMyc antibodies followed by FITC- (donor) and Cy3- (acceptor) conjugated secondary antibodies. Cells expressing HA-hSSTR5 and cMyc-β~2~AR displayed relative FRET efficiency of 10 ± 0.5%, indicating that hSSTR5/β~2~AR exists as preformed heterodimers at basal condition (Figure [2A](#F2){ref-type="fig"} and [3A](#F3){ref-type="fig"}). Interestingly, upon treatment with SST or formoterol alone, cells displayed 3.7 ± 1.3% and 4.2 ± 1.1% of relative FRET efficiency respectively in comparison to control. However, co-activation of hSSTR5 and β~2~AR exhibited 17.4 ± 1% of relative FRET efficiency, significantly higher than the basal level (Figure [2B](#F2){ref-type="fig"} and [3A](#F3){ref-type="fig"}). These data suggest that the simultaneous activation of both the receptors enhanced the formation of heteromeric complex between hSSTR5 and β~2~AR. Similar results were observed when directly labeled HA- and cMyc- antibodies were used in FRET analysis to support that FRET signals were not due to the aggregation of antibodies (data not shown).

![**Microscopic Pb-FRET analysis in HEK-293 cells coexpressing cMyc-β~2~AR/HA-hSSTR5**. **(A)**Representative photomicrographs of HEK-293 cells illustrating cMyc-β~2~AR (red), HA-hSSTR5 (green) and colocalization in merged image (yellow) **(Panel a)**. Pb-FRET microscopy on HEK-293 cells coexpressing cMyc-β~2~AR/HA-hSSTR5 was performed as described in Material and Methods. A selection of photomicrographs illustrating photobleaching profile of donor alone and in the presence of acceptor are shown in **panels b and d**. Histograms shown in **panels c and e**represents pixel by pixel analysis of time constant of donor and donor + acceptor and the mean time constant shown in black was calculated from a Gaussian distribution curve. Note the increased time constant of donor in presence of acceptor, indicating interactions between cMyc-β~2~AR/HA-hSSTR5. **(B)**HEK-293 cells expressing cMyc-β~2~AR/HA-hSSTR5 were treated with SST (1 μM) and formoterol (1 μM) in combination for 15 min at 37°C. Activation of hSSTR5 with SST and β~2~AR with formoterol simultaneously displayed increase in the effective FRET efficiency. Representative photomicrographs illustrating bleaching profile of the donor in the absence or presence of acceptor are shown in **panels b and d**. Histograms shown in **panels c and e**represent pixel by pixel analysis of time constant of the donor alone or donor + acceptor respectively in cells treated with SST and β~2~AR specific agonist together for 15 min. Data are representative of three independent experiments performed in duplicate. Approximately 60-70 cells were analyzed per experiment.](1750-2187-6-9-2){#F2}

![**Histogram and photomicrographs illustrating relative FRET efficiencies and FACS analysis in HEK-293 cells cotransfected with hSSTR5 and β~2~AR**. **(A)**Activation of hSSTR5 with SST or β~2~AR with formoterol displayed decrease in the FRET efficiency indicating the dissociation of receptor complex upon activation of individual receptors. In contrast, upon combined treatment with SST (1 μM) and formoterol (1 μM), cells displayed enhanced heterodimerization. Mean ± S.E. are representative of three independent experiments performed in duplicate. Data analysis was done by using ANOVA and *post hoc*Bonferroni\'s Multiple Comparison test to compare with control and treated conditions. **(B-D)**Approximately 2 × 10^6^cells were treated with receptor specific agonist as indicated in materials and methods section. Cells were washed with FACS buffer, fixed in 4% paraformaldehyde and were processed for immunostaining as described. BD LSRII flow cytometer, configured with a 488 nm and 561 nm laser was used for the experiments. Cy3 labeled cells were used as control **(Panel B)**. Note the increased emission in 610/20 channel when cells were excited with 488 nm laser in control **(Panel C)**as well as upon combined agonist treatment **(Panel D)**.](1750-2187-6-9-3){#F3}

Fluorescence resonance energy transfer analysis by using FACS
-------------------------------------------------------------

To further confirm the results obtained from Co-IP and microscopic Pb-FRET analysis, non-invasive, sensitive and quantitative FACS analysis was employed to determine the receptor heterodimerization in cotransfected cells. Cells were processed as described in Materials and methods. To measure the FRET between SSTR5 and β~2~AR, Cy3- emission at 610/20 was detected upon excitation of FITC with 488 nm laser in double labeled cells (Figure [3B-D](#F3){ref-type="fig"}). As shown in the Figure [3B](#F3){ref-type="fig"}, no significant emission in 610/20 channel was detected when Cy3 labeled cells were excited with 488 nm laser (mean fluorescence intensity = 21.1). In contrast, when both the receptors were labeled with fluorescence conjugated antibodies, excitation with 488 laser in control resulted in the enhanced emission at 610/20 channel displaying mean fluorescence of 26.2, indicating FRET (Figure [3C](#F3){ref-type="fig"}). Upon treatment with receptors specific agonist alone, cells displayed mean fluorescence comparable to Cy3 labeled cells (\~22.0). Interestingly, upon combined agonist treatment, increased FRET was observed with enhanced mean fluorescence of 28.8 indicating fostered heterodimerization (Figure [3D](#F3){ref-type="fig"}). Taken in consideration, these data indicate that heterodimerization observed between SSTR5 and β~2~AR by using Co-IP, Pb-FRET and FACS analysis is receptor specific.

Receptor and agonist dependent internalization of hSSTR5 and β~2~AR using indirect immunofluorescence and FACS analysis
-----------------------------------------------------------------------------------------------------------------------

Previous studies have shown that hSSTR5 and β~2~AR displayed internalization upon agonist treatment \[[@B28],[@B38]\]. Here, we determined the expression pattern of hSSTR5 and β~2~AR at the cell surface and intracellularly in cotransfected cells following treatment with the receptor specific agonists by using indirect immunofluorescence microscopy and FACS analysis. In control cells, hSSTR5 and β~2~AR exhibited strong colocalization at the cell surface than intracellularly (Figure [4A](#F4){ref-type="fig"}). Three different receptor populations were detected intracellularly i.e., either expressing hSSTR5 or β~2~AR and colocalization. hSSTR5 membrane expression was decreased upon treatment with SST and resulted in the loss of receptor colocalization at the cell surface. Increased expression of hSSTR5 was observed intracellularly without any significant effect on β~2~AR membrane expression (Figure [4A](#F4){ref-type="fig"}). In contrast, upon treatment with formoterol, β~2~AR internalized and resulted with the loss of receptor expression at cell surface. This resulted in the loss of colocalization with SSTR5 and increased intracellular expression of β~2~AR (Figure [4A](#F4){ref-type="fig"}). Importantly, simultaneous activation of both receptors displayed no significant changes in the membrane or intracellular expression as well as in colocalization when compared to the control.

![**Representative photomicrographs and FACS analysis illustrating receptor and agonist dependent internalization**. (**A)**The cells displayed colocalization at the membrane in non-permeabilized and intracellularly in permeabilized cells with distinct populations of hSSTR5 (green) and β~2~AR (red). Following treatment with SST, β~2~AR remain unchanged while hSSTR5 displayed agonist induced internalization. Upon activation with formoterol, β~2~AR internalized as indicated by the loss of β~2~AR and colocalization with hSSTR5 at cell surface which is accompanied with the increased intracellular expression. Combined treatment with SST and formoterol displayed colocalization between hSSTR5 and β~2~AR. In all representative photographs DAPI in blue color indicates nuclear staining. Scale bar = 10 μm. **(B)**BD LSRII flow cytometer configured with a 488 nm and 561 nm laser was used for the experiments. Cy3- (β~2~AR expression, **panels b, d, f and h**) was monitored using the 561 nm laser and a 610/20 emission filter whereas 488 nm laser was used to detect SSTR5 expression (FITC, **panels a, c, e and g**) and the emission was detected using a 530/30 filter. Cells were processed as described in materials and methods section. Note the left side shifts in the FITC and Cy3 expression **(Panels c and f)**indicating agonist dependent receptor specific internalization. No significant change in the expression pattern for the receptors was observed upon combined activation with both the ligands **(Panels g and h)**.](1750-2187-6-9-4){#F4}

Microscopic immunofluorescence internalization was further confirmed by using FACS analysis (Figure [4B, a-h](#F4){ref-type="fig"}). In control cells, both the receptors were well expressed on the membrane (Figure [4B, a](#F4){ref-type="fig"} and [4b](#F4){ref-type="fig"}). As shown in **panel c**, a significant decrease in the SSTR5 expression (FITC intensity) upon treatment with SST was observed, without any change in β~2~AR expression **(d)**. Upon treatment with formoterol, β~2~AR expression (Cy3 intensity) was reduced **(f)**, whereas, SSTR5 expression remained unaffected **(e)**. In combined treatment with both the agonist, no significant change in the emission at 530/30 and 610/20 filters was observed in comparison to control (Figure [4B, g](#F4){ref-type="fig"} and [4h](#F4){ref-type="fig"}). Taken together, results from immunofluorescence and FACS analysis indicate that agonist induced internalization of β~2~AR and SSTR5 is receptor specific and is independent of each other.

Inactivation of β~2~AR is required for the inhibition of cAMP via hSSTR5
------------------------------------------------------------------------

To better understand the molecular mechanism of this interaction, we first determined the changes in receptor coupling to AC in mono and/or cotransfected cells. In basal condition, cells transfected with β~2~AR showed relatively higher cAMP formation (2.99 ± 0.2 picomole/mg protein) in comparison to the cells transfected with hSSTR5 (1.3 ± 0.3 picomole/mg protein) (Figure [5A](#F5){ref-type="fig"}). In the presence of FSK, cells expressing β~2~AR or hSSTR5 displayed 7.9 ± 0.3 and 5.07 ± 0.41 picomole/mg protein of cAMP respectively. Monotransfected cells expressing hSSTR5 displayed inhibition of FSK stimulated cAMP levels by 55 ± 3% and 54 ± 3% upon treatment with SST and hSSTR5 specific agonist (L-817818) respectively (Figure [5A](#F5){ref-type="fig"}). In contrast, level of cAMP increased by \~3 folds (8.23 ± 0.5 picomole/mg protein) in β~2~AR monotransfected cells upon formoterol treatment. In cotransfected cells, the basal intracellular cAMP level (1.65 ± 0.2 picomole/mg protein) was elevated by \~4 folds in the presence of formoterol (8.4 ± 0.4 picomole/mg protein) (Figure [5B](#F5){ref-type="fig"}). Upon treatment with SST or L-817818, FSK stimulated cAMP was inhibited by 8.6 ± 0.3% and 9 ± 1.5% respectively. Conversely, following treatment with formoterol, FSK stimulated cAMP was increased by 6 ± 1%. Upon combined treatment with SST or L-817818 and formoterol cells displayed 7 ± 0.5% and 8.6 ± 1% increased cAMP in the presence of FSK. Most importantly, blockade of β~2~AR with receptor specific antagonist ICI-118551 (5 nM) in presence of SST resulted in enhanced inhibition of FSK stimulated cAMP levels by 23 ± 1.6% (Figure [5C](#F5){ref-type="fig"}). These data suggest that blockade of β~2~AR is essential for the inhibitory role of SST in cotransfected cells.

![**Inactivation of β~2~AR enhanced hSSTR5 coupling to adenylyl cyclase**. Mono-and/or cotransfected HEK-293 cells were processed as described in materials and methods. In basal condition, cAMP level was relatively higher in cells expressing β~2~AR **(Panel A)**in comparison to hSSTR5 expressing cells **(Panel A)**. However, both the cell lines displayed increased cAMP in the presence of FSK. As shown, SSTR5 transfected cells exhibited the inhibition of cAMP in presence of SST and SSTR5 specific agonist. In cotransfected cells, basal level of cAMP was comparable to hSSTR5 expressing cells **(Panel B)**. Note the significant decrease in cAMP with SST in presence of β~2~AR antagonist **(Panel C)**. Mean ± S.E. are representative of three independent experiments performed in triplicate. Data analysis was done by using ANOVA and *post hoc*Dunnett\'s to compare against basal level (\*, *p*\< 0.01).](1750-2187-6-9-5){#F5}

Identification of G-Proteins involved in receptor coupling
----------------------------------------------------------

GPCR coupling to AC is regulated by different G proteins including G~s~, G~i~, G~q~and G~12~that play determinant role on intracellular cAMP levels. β-ARs typically interact with G~s~whereas SSTRs have been shown to couple G~i~. Excellent observations from Lefkowitz\'s laboratory and others have described that β~1~AR/β~2~AR also couple to G~i~and activate signaling pathways in distinct manner than G~s~\[[@B17],[@B39]\]. To ascertain the specificity of G proteins involved in β~2~AR and SSTR5 mediated regulation of cAMP, we used G~s~inhibitors GPAP and Melittin and G~i~inhibitor PTX \[[@B40]-[@B42]\]. Mono and/or cotransfected cells were treated with GPAP, Melittin and PTX as described in methods section. As shown in Figure [6A](#F6){ref-type="fig"}, cells expressing β~2~AR displayed increased levels of cAMP by \~125% in presence of FSK or formoterol, the effect which was completely abrogated upon treatment with GPAP and Melittin. β~2~AR stimulated cAMP was not affected in presence of PTX in monotransfected cells (Figure [6A](#F6){ref-type="fig"}). SST mediated effect on cAMP inhibition was completely abrogated upon PTX treatment in SSTR5 monotransfected cells, whereas, GPAP and Melittin had no significant effect on cAMP levels (Figure [6A](#F6){ref-type="fig"}). These data in concurrence with previous studies indicate that β~2~AR and SSTR5 are coupled to G~s~and G~i~respectively \[[@B17],[@B43]\]. In cotransfected cells, increased level of cAMP upon treatment with formoterol was abolished in presence of G~s~inhibitors GPAP and Melittin but not with PTX whereas, SST mediated inhibition of cAMP in presence of β~2~AR antagonist ICI was blocked with PTX (Figure [6B](#F6){ref-type="fig"}). Interestingly, SST displayed inhibition of cAMP by 25% and 27% in the presence of GPAP and Melittin respectively. These observations indicate that β~2~AR is predominantly coupled to G~s~in monotransfected as well as in cotransfected cells whereas, SSTR5 mediated regulation of cAMP is mediated by G~i~protein.

![**Specificity of G protein coupling**. Mono-and cotransfected cells were treated with G~s~inhibitors GPAP (5 μM) and Melittin (1 μM) for 2 h; 100 ng/ml PTX (G~i~inhibitor) for 16-18 h in DMEM at 37°C and processed for cAMP estimation. GPAP and Melittin resulted in complete loss of formoterol induced cAMP levels, whereas PTX had no significant effect on increased cAMP levels upon formoterol treatment in mono and/or cotransfected cells **(Panels A and B)**. In contrast regulation of cAMP levels by SSTR5 were completely abrogated upon PTX treatment in mono or cotransfected cells. Mean ± S.E. are representative of three independent experiments performed in triplicate. Data analysis was done by using ANOVA and *post hoc*Dunnett\'s to compare against basal level (\*, *p*\< 0.05; \*\*, *p*\< 0.01).](1750-2187-6-9-6){#F6}

Differential regulation of Protein kinase A by hSSTR5 and β~2~AR
----------------------------------------------------------------

Previous studies have suggested the critical role of PKA in switching of G protein coupling of β~2~AR \[[@B44]\]. PKA upon activation phosphorylates β~2~AR at specific C-terminal domains which in turn promotes switching of receptor coupling from G~s~to G~i~, thus activating different signaling cascade \[[@B44]\]. To activate cAMP/PKA pathway mono-and/or cotransfected cells were grown in presence of basal Ca^2+^(1.8 mM) as well as in high concentration of Ca^2+^(2.5 mM) and cells were processed to determine the status of PKA phosphorylation. As shown in Figure [7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}, β~2~AR or hSSTR5 monotransfected cells displayed receptor and agonist specific changes on PKA phosphorylation in presence of basal Ca^2+^. In β~2~AR monotransfected cells, formoterol decreased PKA phosphorylation upon 10 and 30 min treatment in comparison to control. In contrast, cells expressing hSSTR5 exhibited significantly decreased PKA phosphorylation in presence of SST at 10 min, whereas upon 30 min treatment phospho-PKA was comparable to control. In cotransfected cells, PKA phosphorylation was decreased upon 10 min treatment with formoterol alone or in combination with SST or SSTR5 agonist in comparison to control. However, following treatment for 30 min, the level of phospho-PKA was decreased significantly in comparison to control (Figure [7B](#F7){ref-type="fig"}). These results suggest that in cotransfected cells, β~2~AR mediated inhibition of phospho-PKA was predominant.

![**Time and receptor specific changes in PKA phosphorylation**. To determine the expression levels of total and phospho-PKA, mono-and cotransfected cells were treated with SST, L-817818 and formoterol alone or in combination for 10 and 30 min at 37°C in the presence of basal **(Panels A and B)**and higher Ca^2+^**(Panel C)**. Upon 10 min treatment, cells expressing hSSTR5 displayed inhibition of PKA phosphorylation in the presence of SST whereas no significant phosphorylation of PKA was detected in cells expressing β~2~AR. In cotransfected cells, β~2~AR effect was predominant showing inhibition of pPKA with all treatments as indicated **(Panel A)**. Interestingly, PKA phosphorylation was enhanced in SSTR5 monotransfectant in control or in presence of SST for 30 min. With high Ca^2+^in culture medium, pPKA expression was higher in the presence of β~2~AR in comparison to hSSTR5 and was inhibited upon activation of receptors respectively. In cotransfected cells, enhanced PKA phosphorylation seen in monotransfected cells was completely diminished following agonist treatment **(Panel C)**. Densitometric analysis of western blot for pPKA is shown. Data analysis was done by using ANOVA and *post hoc*Dunnett\'s to compare against basal level (\*, *p*\< 0.01).](1750-2187-6-9-7){#F7}

In comparison, at high Ca^2+^concentration in culture medium, the level of phospho-PKA increased in cells expressing β~2~AR and decreased in hSSTR5 transfected cells when compared to basal Ca^2+^concentration. SST or formoterol caused decrease in PKA phosphorylation in monotransfected cells (Figure [7C](#F7){ref-type="fig"}). However, cotransfected cells displayed complete inhibition of phospho-PKA upon treatment with SST, L-817818 (SSTR5 agonist) and formoterol alone or in combination. The effect observed in presence of high Ca^2+^indicates the blockade of cAMP/PKA mediated pathway with predominant role of β~2~AR.

Receptor specific dependency in regulation of ERK1/2 phosphorylation
--------------------------------------------------------------------

The MAPK represents a critical signal transduction cascade involved in multitude of cellular processes and upon distinctive activation plays an important role in responding to the growth and stress stimuli \[[@B45]\]. To ascertain whether receptor heterodimerization and the changes in cAMP/PKA regulate downstream signaling cascades, we next examined the status of key MAPKs i.e., ERK1/2 and p38 in mono-and cotransfected HEK-293 cells. As shown in Figure [8A](#F8){ref-type="fig"}, the activation of β~2~AR and hSSTR5 enhanced phosphorylation of ERK1/2 in monotransfected cells. This effect was relatively more pronounced in SSTR5 transfected cells following treatment with SST for 10 and 30 min (Figure [8A](#F8){ref-type="fig"} and [8B](#F8){ref-type="fig"}). In comparison to monotransfectant, the cells coexpressing both the receptors, ERK1/2 phosphorylation was receptor and time dependent with the prominent effect of SST or SSTR5 agonist in combination with formoterol upon 10 min treatment (Figure [8A](#F8){ref-type="fig"} and [8B](#F8){ref-type="fig"}). In contrast, upon 30 min treatment with SST, L-817818 and formoterol alone or in combination, cells displayed decreased expression of phospho-ERK1/2 in comparison to 10 min treatment (Figure [8B](#F8){ref-type="fig"}). These results strongly support the G~i~mediated activation of phospho-ERK1/2 at early time point (10 min) whereas upon treatment for 30 min phospho-ERK1/2 is predominantly regulated by β~2~AR in heteromeric complex. Densitometric analysis was performed to quantify changes in phospho-ERK1/2 expression is presented in Figure [8C](#F8){ref-type="fig"} and [8D](#F8){ref-type="fig"}.

![**Receptor mediated changes in ERK1/2 and p38 phosphorylation**. Mono-and cotransfected HEK-293 cells were treated with SST (1 μM), L-817818 (10 nM) and formoterol (1 μM) alone or in combination at 37°C for 10 and 30 min **(Panels A and B)**. In monotransfected cells, increased expression of pERK1/2 was observed with more significant changes in SSTR5 expressing cells. Similar pattern was also seen following 30 min incubation albeit to the lesser degree. In comparison, cotransfected cells displayed discernable changes at 10 or 30 min treatments **(Panels A and B)**. Densitometric analysis of western blot is shown for ERK1/2 **(Panels C and D)**. Data analysis was done by using ANOVA and *post hoc*Dunnett\'s to compare against basal level (\*, *p*\< 0.01). As shown in **panels E and F**, no significant expression of phosphorylated p38 was observed in mono-and/or cotransfected HEK-293 cells with or without treatment. Data are representative of three independent experiments.](1750-2187-6-9-8){#F8}

Changes in p38 expression in cells expressing hSSTR5 and β~2~AR
---------------------------------------------------------------

Several previous studies have described that changes in the p38 expression are associated with pro and/or anti-apoptotic effects in receptor and tissue specific manner \[[@B45]\]. β~2~AR coupling to G~i~has been appreciated for its role in cell survival pathway due to anti-apoptotic action other than G~s~mediated signaling. In contrast, hSSTR5 is shown to exert antiproliferative effects. Whether or not β~2~AR encounter or potentiate this effect of hSSTR5 in cotransfected cells is not known. Here, we examined the status of phospho-p38 in mono-and cotransfected cells expressing β~2~AR and hSSTR5. Monotransfected cells displayed weak expression of phospho-p38 upon receptor specific activation at 10 min in comparison to control (Figure [8E](#F8){ref-type="fig"}). Following 30 min incubation in presence of receptor specific agonists phosphorylated p38 was not detected despite the expression of total p38 as indicated (Figure [8F](#F8){ref-type="fig"}). The phospho-p38 was not detected in cotransfected cells with or without receptor specific activation alone or in combination following 10 or 30 min treatments, whereas expression level of total p38 remained comparable in all the conditions as indicated in Figure [8E](#F8){ref-type="fig"} and [8F](#F8){ref-type="fig"}.

The presence of β~2~AR and hSSTR5 regulates dephosphorylation and nuclear translocation of NFAT
-----------------------------------------------------------------------------------------------

Calcium mediated activation of Calcineurin induces dephosphorylation of NFAT transcription factor in the cytoplasm and increased dephosphorylation persuade its nuclear translocation which is associated with activation of several gene expression \[[@B46]\]. Accordingly, in this experiment we compared the expression of phospho-NFAT in mono-and/or cotransfected HEK-293 cells. As shown in Figure [9A](#F9){ref-type="fig"}, no significant changes in the expression of pNFAT were observed when β~2~AR or hSSTR5 monotransfected cells were treated with receptor specific agonists in presence of basal Ca^2+^. Comparable expression of phospho-NFAT was observed in β~2~AR and hSSTR5 cotransfected cells in control as well as treated conditions as indicated. However, the status of NFAT phosphorylation was elevated in HEK-293 cells expressing hSSTR5 or β~2~AR in presence of high Ca^2+^with no significant effect of receptor specific activation (Figure [9B](#F9){ref-type="fig"}). In cotransfected cells, Formoterol treatment enhanced the phosphorylation of NFAT significantly whereas SST or L-817818 alone or in combination with Formoterol the expression of phospho-NFAT was comparable to control. To quantify the changes in phospho-NFAT expression, densitometric analysis was performed (Figure [9C](#F9){ref-type="fig"} and [9D](#F9){ref-type="fig"}). These results provide direct evidence that β~2~AR and hSSTR5 ablated calcineurin mediated dephosphorylation and nuclear translocation of NFAT.

![**hSSTR5 and β~2~AR blocks the dephosphorylation of NFAT**. Mono-and cotransfected HEK-293 cells were treated with SST (1 μM), L-817818 (10 nM), β~2~agonist (1 μM) alone or in combination at 37°C for 30 min and analyzed for total and phosphorylated NFAT in presence of basal and elevated Ca^2+^. In the presence of basal Ca^2+^no significant changes were seen in NFAT phosphorylation in mono-and/or cotransfected cells expressing β~2~AR or hSSTR5 **(Panel A)**. In the presence of high Ca^2+^in culture medium, increased level of phosphorylated NFAT was observed in monotransfected cells when compared with basal Ca^2+^control. Cotransfected cells displayed increased phospho-NFAT upon formoterol treatment whereas NFAT phosphorylation remained comparable to control upon activation of SSTR5 alone or in combination with β~2~AR agonist **(Panel B)**. Densitometric analysis of western blot for pNFAT is shown in **panels C and D**. Data analysis was done by using ANOVA and *post hoc*Dunnett\'s to compare against control (\*, *p*\< 0.05).](1750-2187-6-9-9){#F9}

Discussion
==========

In the present study, we describe the heterodimerization between β~2~AR and hSSTR5 in stably cotransfected HEK-293 cells and characterized its role on key signaling pathways. Our study showed that β~2~AR and hSSTR5 exist as preformed heterodimers in basal condition and regulate receptor trafficking, coupling to AC and modulate the signaling cascades in receptor and time dependent manner. Although, β~2~AR has been studied extensively as a model of receptor dimerization, present study revealed for the first time that β~2~AR and hSSTR5 can function synergistically on selective MAPKs and cAMP dependent protein kinase A. Significantly, the effects of SSTR5 in association with β~2~AR are completely different from the hSSTR5/β~1~AR heterodimers as described recently \[[@B35]\].

The heterodimerization between chemokine receptor 4 and opioid receptor is stabilized in the presence of ligands for both protomers whereas, the activation of individual receptor prompted dissociation of heterodimeric complex and leads to the inactivation of signaling pathway \[[@B47]\]. In agreement with these observations by using conventional co-immunoprecipitation, microscopic Pb-FRET and FACS analysis, here we describe that β~2~AR/hSSTR5 exists as heterodimers in basal condition and heterodimerization was disrupted upon activation of β~2~AR or hSSTR5 alone. Devi et al., described that simultaneous activation of opioid receptor and β~2~AR enhanced the heterodimerization \[[@B27]\]. Consistent with these observations, we here describe that synergistic activation of β~2~AR and hSSTR5 resulted in enhanced heterodimerization while activation of individual receptor was devoid of such effect \[[@B27]\]. Interestingly, this is just opposite to our recent study demonstrating that co-activation of hSSTR2/hSSTR5 is not required for heterodimerization and the activation of single protomer is fully capable to exhibit the formation of heterooligomers \[[@B24]\]. Increased FRET efficiency upon activation of both receptors suggests the changes in conformation and orientation of receptor distribution at cell surface. In contrast, the activation of single receptor prompted the dissociation and resulted in loss of FRET efficiency. Consistent with these observations, we have recently shown the activation of individual receptor in cells cotransfected with β~1~AR/hSSTR5 promotes the formation of homodimers preferentially over heterodimerization of the receptors \[[@B35]\].

FACS is emerging as one of the most modern and reliable technique for determining fluorescence resonance energy transfer along with quantification of cell surface expression of receptors. FACS is highly sensitive and large number of cells live or fixed can be analyzed in a short duration of time \[[@B48]\]. We took an advantage of the versatility of FACS, and determined the FRET between β~2~AR and hSSTR5 upon treatment with receptor specific agonist alone or in combination. The FACS-FRET is quantitative, highly accurate, reproducible method and the results obtained further supports the data procured from the classical method like Co-IP or the state of art biophysical method Photobleaching-FRET analysis.

Receptor heterodimerization at the cell surface serves as regulatory mechanism for receptor expression and receptor specific internalization in presence of specific ligand \[[@B49]-[@B51]\]. As shown earlier, β~2~AR exhibits internalization in agonist dependent manner whereas β~1~AR is confined at the cell surface and impairs β~2~AR internalization in β~1~AR/β~2~AR cotransfected cells \[[@B28]\]. SSTR subtypes upon ligand induced activation displayed receptor specific internalization in time and temperature dependent manner except hSSTR1 that is rather upregulated at cell surface and only internalize with hSSTR5 in heteromeric complex \[[@B38]\]. We have recently shown that β~1~AR regulates internalization of hSSTR5 which displays colocalization at the cell surface \[[@B35]\]. Here, we described that cells cotransfected with β~2~AR and hSSTR5 exhibit β~2~AR or SSTR5 internalization upon receptor specific activation. Most importantly, synergistic activation of both receptors exhibit strong colocalization at cell surface and may account for enhanced FRET efficiency as discussed above. Our results are consistent with previous study describing the receptor specific internalization and trafficking of β~2~AR and δ or κ opioid receptors in heterodimeric complex \[[@B27]\].

All five human SSTR subtypes inhibit adenylyl cyclase-cAMP via pertussis toxin-sensitive G~i~proteins \[[@B37]\]. In contrast, ARs are positive regulators of AC via coupling to G~s~\[[@B44]\]. However, β~1~AR and β~2~AR upon heterodimerization display no significant changes in cAMP levels in comparison to monotransfected cells \[[@B28]\]. Interestingly, β~2~AR can also couple to G~i~and inhibit AC activity \[[@B52]\]. In addition, selective activation of β~2~AR in the cells coexpressing OR/β~2~AR increased cAMP whereas, activation of ORs resulted in the inhibition of cAMP \[[@B27]\]. Our results strongly support the notion that presence of both receptor subtypes exerts opposing effect in regulation of cAMP with prominent role of β~2~AR upon combined treatment. Most importantly, blockade of β~2~AR in the presence of β~2~AR antagonist enhanced the inhibitory role of SST on FSK stimulated cAMP. Our observations implicate that inactivation of β~2~AR is the prerequisite to unmask the SST mediated inhibitory role in regulation of cAMP levels in cells cotransfected with β~2~AR and SSTR5. These results are consistent with our previous study describing the effect of β~1~AR and SSTR5 on cAMP regulation although the inhibitory effect of SST was more pronounced in β~1~AR/SSTR5 transfected cells \[[@B35]\].

The activation of cAMP/PKA, MAPK and calcineurin dependent NFAT dephosphorylation and nuclear translocation of NFAT are intimately associated events in regulation of adrenergic receptor functions. PKA expression is suppressed upon activation of SSTRs suggesting that cAMP/PKA is inhibited due to the activation of G~i~. Although, β~2~AR mediated activation of cAMP/PKA is well established via coupling to G~s~however, the role of G proteins coupling in cotransfected cells has not been studied in detail. The results described here indicate that heterodimerization may not involve in promoting switching of G protein Coupling. Further in addition, previous studies have shown that β~2~AR coupling to dual G proteins shifts towards G~i~upon PKA mediated phosphorylation of β~2~ARs \[[@B44]\]. This transition from G~s~to G~i~is most controversial and poorly understood and further studies are required to resolve such discrepancies. Recently, using Fluorescence fluctuations of quantum-dot sensors report that β~2~AR agonist mediated PKA activation is completed within 3s \[[@B53]\]. Whether prolonged activation of β~2~AR involved in this transition is not known. Taken together, the time dependent changes described here suggest that activation of PKA at early time points might be sufficient enough to phosphorylate β~2~AR to involve G~i~mediated effect which may partially recover upon 30 min. Most importantly, in cotransfected cells, complete inhibition of PKA phosphorylation at high Ca^2+^further strengthens the concept of G~i~mediated coupling of both the receptor subtypes. These data strongly suggest the crucial role of hSSTR5/β~2~AR heterodimerization is attributed to G~i~mediated effect of β~2~AR. The results presented here are significantly distinct from the β~1~AR/SSTR5 transfected cells, as the activation of SSTR5 enhanced PKA phosphorylation and Isoproterenol treatment resulted in inhibition of PKA phosphorylation in cotransfected cells \[[@B35]\].

In addition to receptor coupling to cAMP and PKA phosphorylation, the changes in MAPKs including phosphorylation of ERK1/2 and p38/JNK pathways have been studied extensively as functional consequence of GPCR activation and dimerization. In contractile cells, G~i~mediated activation of ERK via GPCRs has been reported \[[@B54]\]. Consistent with these studies, β~2~AR internalization is associated with the inhibition of ERK phosphorylation \[[@B28]\]. Here, we describe the sustained activation of ERK1/2 in cells expressing hSSTR5 and β~2~AR upon synergistic activation of hSSTR5/β~2~AR. Such activation of ERK directly correlates with receptor heterodimerization. Whether or not this effect of SSTR5 is associated with anti-proliferative effect of SST via activation of ERK needs to be determined. Interestingly, the effect of β~1~AR or β~2~AR agonist on the phosphorylation of ERK1/2 has significantly diverse effects. As previously shown, Isoproterenol treatment resulted in increased phospho-ERK1/2 expression, whereas formoterol has inhibitory effect on phosphorylation of ERK1/2 \[[@B35]\].

Consistent with the changes in ERK1/2, the loss of p38 in cotransfected cells is governed with the prominent role of hSSTR5. Taken together increased ERK1/2 and loss in p-p38 expression might implicate in inhibition of cell proliferation. An antagonist of p38 (SB203580) reduce the agonist induced hypertrophy and reduced p38 signaling in the heart promote myocyte growth through a mechanism involving enhanced calcineurin-NFAT signaling \[[@B45]\]. Thus, calcineurin-NFAT and JNK signaling pathways crosstalk represents a critical mechanism that regulate cell physiology specifically in cells of cardiac origin \[[@B46]\]. HEK-293 cells express calcineurin endogenously and its inactivation inhibits NFAT dephosphorylation and translocation to nucleus, the process which is regulated by Ca^2+^\[[@B55]-[@B57]\]. In case of β~1~AR/hSSTR5 heterodimers, the dominant role of SSTR5 was evident as β~1~AR activation resulted in loss of pNFAT levels whereas SSTR5 displayed consistent expression of pNFAT \[[@B35]\]. We here describe that upon formation of β~2~AR/hSSTR5 heterodimers, NFAT dephosphorylation is blocked significantly and both the receptors contribute equally to exert this effect. Increased NFAT phosphorylation in cotransfected cells provides the first evidence that β~2~AR/hSSTR5 heterodimers blocks NFAT dephosphorylation and its nuclear translocation.

Although, SSTR5 heterodimerizes with β~1~AR as well as β~2~AR however, it exhibit distinct regulation of signaling pathways in both the cases. In cells transfected with β~1~AR/SSTR5, the role of SSTR5 in regulation of signaling is predominant whereas in cells transfected with β~2~AR/SSTR5, the effect of SSTR5 is synergistic. In conclusion, data presented here provides new insight for the role of hSSTR5 and β~2~AR which might have physiological significance and therapeutic implications in cardiac physiology in pituitary tumor and Huntington disease. The results presented in this study specifically changes in signaling pathways including cAMP, PKA, ERK1/2 and NFAT in hSSTR5/β~2~AR complex are quite interesting. Whether SSTRs and β-ARs colocalize in cardiac tissue *in vivo*is largely elusive and further studies are warranted prior to draw any conclusion for the role of SSTRs and β-ARs in this direction.
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